Now, there may be another option for him. It's a drug called tirzepatide, also known as Mounjaro or Zepbound. It's FDA approved to manage diabetes and obesity. Now, UC San Diego researchers have ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

This post hoc analysis of the SURMOUNT-1 study, at three years, aimed to assess weight regain from nadir weight over three years (36 months / 176 weeks) with tirzepatide treatment. Weight regain ...

Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart failure with few treatment options, in another big win for the GLP-1 ...

This post hoc analysis of the SURMOUNT-1 study, at 3 years, aimed to assess weight regain from nadir weight over 3 years (36 months / 176 weeks) with tirzepatide treatment. The original SURMOUNT-1 ...

Opens in a new tab or window Patients with poorly controlled type 2 diabetes despite being on dulaglutide had better outcomes if they switched to tirzepatide than if they upped their dulaglutide dose.

Jessica Baylis, 44, of Greenlawn, who has lost nearly 40 pounds since she began taking compounded tirzepatide in 2023, said she would have difficulty paying name-brand prices. Zepbound and ...

Switching to tirzepatide linked to additional reduction in HbA1c, weight loss compared with escalating dulaglutide. HealthDay News — For patients with inadequately controlled type 2 diabetes ...

Participants given tirzepatide lowered their HbA1c by a mean 0.77% more than those given a higher dulaglutide dose. More tirzepatide participants hit a weight loss threshold known for disease ...

The proposed dosages ranged from 2.5 mg to 15 mg. Tirzepatide had already received approval in a single-dose prefilled pen format in January 2024, for use as an adjunct to diet and exercise to ...

NEW ORLEANS — For people with type 2 diabetes (T2D) inadequately controlled on submaximal dulaglutide (Trulicity) doses, switching to tirzepatide (Mounjaro) produces significantly greater A1c ...